A Phase 1 Study of TAK-676, a Novel STING Agonist, Plus Pembrolizumab Following Radiation Therapy in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC), Triple-Negative Breast Cancer (TNBC), or Squamous-Cell Carcinoma of the Head and Neck (SCCHN)

A Phase 1 Study of TAK-676, a Novel STING Agonist, Plus Pembrolizumab Following Radiation Therapy in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC), Triple-Negative Breast Cancer (TNBC), or Squamous-Cell Carcinoma of the Head and Neck (SCCHN)

Saved in:
Bibliographic Details
Published in:International journal of radiation oncology, biology, physics Vol. 114; no. 3; p. e40
Main Authors: Gerber, N.K., Chmura, S.J., Luke, J.J., Shiao, S.L., Basho, R., Iams, W.T., Page, D.B., Li, C., Gregory, R.C., Shaw, M.H., Horn, K.H., Gibbs, J., Appleman, V.A., Berger, A., Abu-Yousif, A.O., Lineberry, N.B., Stumpo, K.F., Elfiky, A., Cooper, B.
Format: Journal Article
Language:English
Published: 01-11-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0360-3016
DOI:10.1016/j.ijrobp.2022.07.762